Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), and Generally Recognized as Safe Affirmation; Submission of Information to a Master File in Support of Petitions; Electronic Submission Using Food and Drug Administration Form 3503, 33624-33626 [2010-14155]
Download as PDF
33624
Federal Register / Vol. 75, No. 113 / Monday, June 14, 2010 / Notices
Dated: June 8, 2010.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–14158 Filed 6–11–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0258]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Submission of
Petitions: Food Additive, Color
Additive (Including Labeling), and
Generally Recognized as Safe
Affirmation; Submission of Information
to a Master File in Support of Petitions;
Electronic Submission Using Food and
Drug Administration Form 3503
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
emcdonald on DSK2BSOYB1PROD with NOTICES
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection provisions of
FDA’s regulations for submission of
petitions, including food and color
additive petitions (including labeling)
and generally recognized as safe (GRAS)
affirmations, submission of information
to a Master File in support of petitions,
and electronic submission using FDA
Form 3503. This notice also notifies the
public of and solicits comments on
FDA’s proposed changes to Form FDA
3503 and elimination of Form FDA
3504.
DATES: Submit either electronic or
written comments on the collection of
information by August 13, 2010.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
VerDate Mar<15>2010
16:40 Jun 11, 2010
Jkt 220001
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Submission of Petitions: Food Additive,
Color Additive (Including Labeling),
and GRAS Affirmation; Submission of
Information to a Master File in Support
of Petitions; Electronic Submission
Using FDA Form 3503—21 CFR 70.25,
71.1, 170.35, 171.1, 172, 173, 179, and
180 (OMB Control Number 0910–
0016)—Revision
Section 409(a) of the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 348(a)) provides that a food
additive shall be deemed to be unsafe,
unless: (1) The additive and its use, or
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
intended use, are in conformity with a
regulation issued under section 409 of
the act that describes the condition(s)
under which the additive may be safely
used; (2) the additive and its use, or
intended use, conform to the terms of an
exemption for investigational use; or (3)
a food contact notification submitted
under section 409(h) of the act is
effective. Food additive petitions (FAPs)
are submitted by individuals or
companies to obtain approval of a new
food additive or to amend the
conditions of use permitted under an
existing food additive regulation.
Section 171.1 of FDA’s regulations (21
CFR 171.1) specifies the information
that a petitioner must submit in order to
establish that the proposed use of a food
additive is safe and to secure the
publication of a food additive regulation
describing the conditions under which
the additive may be safely used. Parts
172, 173, 179, and 180 (21 CFR parts
172, 173, 179, and 180) contain labeling
requirements for certain food additives
to ensure their safe use.
Section 721(a) of the act (21 U.S.C.
379e(a)) provides that a color additive
shall be deemed to be unsafe unless the
additive and its use are in conformity
with a regulation that describes the
condition(s) under which the additive
may safely be used, or the additive and
its use conform to the terms of an
exemption for investigational use issued
under section 721(f) of the act. Color
additive petitions (CAPs) are submitted
by individuals or companies to obtain
approval of a new color additive or a
change in the conditions of use
permitted for a color additive that is
already approved. Section 71.1 of the
agency’s regulations (21 CFR 71.1)
specifies the information that a
petitioner must submit to establish the
safety of a color additive and to secure
the issuance of a regulation permitting
its use. FDA’s color additive labeling
requirements in § 70.25 (21 CFR 70.25)
require that color additives that are to be
used in food, drugs, devices, or
cosmetics be labeled with sufficient
information to ensure their safe use.
FDA scientific personnel review FAPs
to ensure the safety of the intended use
of the additive in or on food or that may
be present in food as a result of its use
in articles that contact food. Likewise,
FDA personnel review color additive
petitions to ensure the safety of the
color additive prior to its use in food,
drugs, cosmetics, or medical devices.
Under section 201(s) of the act (21
U.S.C. 321(s)), a substance is GRAS if it
is generally recognized among experts
qualified by scientific training and
experience to evaluate its safety, to be
safe through either scientific procedures
E:\FR\FM\14JNN1.SGM
14JNN1
33625
Federal Register / Vol. 75, No. 113 / Monday, June 14, 2010 / Notices
or common use in food. The act
historically has been interpreted to
permit food manufacturers to make their
own initial determination that use of a
substance in food is GRAS and
thereafter seek affirmation of GRAS
status from FDA. FDA reviews petitions
for affirmation of GRAS status that are
submitted on a voluntary basis by the
food industry and other interested
parties under authority of sections 201,
402, 409, and 701 of the act (21 U.S.C.
342, 348, and 371). To implement the
GRAS provisions of the act, FDA has set
forth procedures for the GRAS
affirmation petition process in
§ 170.35(c)(1) of its regulations (21 CFR
170.35(c)(1)). While the GRAS
affirmation petition process still exists,
FDA has not received a GRAS
affirmation petition since the
establishment of the voluntary GRAS
notification program and is not
expecting any during the period covered
by this proposed extension of collection
of information.
Currently, interested persons may
transmit regulatory submissions to the
Office of Food Additive Safety in the
Center for Food Safety and Applied
Nutrition using Form FDA 3503 for FAP
and Form FDA 3504 for CAP. FDA is
revising Form FDA 3503 to better enable
its use for electronic submission and to
permit its use for multiple types of
submissions, which eliminates the need
for Form FDA 3504. Because Form FDA
3503 helps the respondent organize
their submission to focus on the
information needed for FDA’s safety
review, FDA now recommends that this
form be used for FAPs and CAPs,
whether submitted in electronic format
or paper format. FDA estimates that the
amount of time for respondents to
complete the revised FDA Form 3503
will continue to be 1 hour. The revised
Form FDA 3503 can be used to submit
information to FDA in electronic format
using the Electronic Submission
Gateway portal. The revised Form FDA
3503 can be used to substitute for the
‘‘Dear Sir’’ section of 21 CFR 71.1(c) for
a CAP and 21 CFR 171.1(c) for an FAP.
The revised Form FDA 3503 provides
for submitters to indicate the date of
their most recent presubmission
consultation activity with FDA. The
revised Form FDA 3503 can also be
used to organize information within a
Master File submitted in support of
petitions according to the items listed
on the form. Master Files can be used as
repositories for information that can be
referenced in multiple submissions to
the agency, thus minimizing paperwork
burden for food and color additive
approvals. The revised Form FDA 3503
is formatted to accept submissions for
both FAP and CAP, thus making Form
FDA 3504 redundant for collecting CAP
submissions. Therefore, FDA is
eliminating Form FDA 3504.
Description of respondents:
Respondents are businesses engaged in
the manufacture or sale of food, food
ingredients, color additives, or
substances used in materials that come
into contact with food.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section/
FDA Form
No. of
Respondents
Annual Frequency
per Response
Total Annual
Responses
Hours
per Response
Total Operating
& Maintenance Costs
Total Hours
CAPs
70.25,71
2
1
2
1,337
$5,600
2,674
1 or fewer
1
1 or fewer
2,614
0
2,614
3
1
3
7,093
0
21,279
6
1
6
1
0
6
$5,600
26,573
GRAS Affirmation Petitions
170.35
FAPs
171.1
FDA Form 3503
Total
emcdonald on DSK2BSOYB1PROD with NOTICES
1 There
are no capital costs associated with this collection of information.
The estimate of burden for food
additive, color additive, or GRAS
affirmation petitions is based on FDA’s
experience and the average number of
new petitions received in calendar years
2006, 2007, 2008, and 2009, and the
total hours expended in preparing the
petitions. In compiling these estimates,
FDA consulted its records of the number
of petitions received in the past four
years. The figures for hours per response
are based on estimates from experienced
persons in the agency and in industry.
Although the estimated hour burden
varies with the type of petition
submitted, an average petition involves
analytical work and appropriate
toxicological studies, as well as the
VerDate Mar<15>2010
16:40 Jun 11, 2010
Jkt 220001
work of drafting the petition itself. The
burden varies depending on the
complexity of the petition, including the
amount and types of data needed for
scientific analysis.
Color additives are subjected to
payment of fees for the petitioning
process. The listing fee for a color
additive petition ranges from $1,600 to
$3,000, depending on the intended use
of the color and the scope of the
requested amendment. A complete
schedule of fees is set forth in 21 CFR
70.19. An average of one Category A and
one Category B color additive petition is
expected per year. The maximum color
additive petition fee for a Category A
petition is $2,600 and the maximum
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
color additive petition fee for a Category
B petition is $3,000. Because an average
of 2 color additive petitions are
expected per calendar year, the
estimated total annual cost burden to
petitioners for this startup cost would be
less than or equal to $5,600 (1 x $2,600
+ 1 x $3,000 listing fees = $5,600). There
are no capital costs associated with
color additive petitions.
The labeling requirements for food
and color additives were designed to
specify the minimum information
needed for labeling in order that food
and color manufacturers may comply
with all applicable provisions of the act
and other specific labeling acts
administered by FDA. Label information
E:\FR\FM\14JNN1.SGM
14JNN1
33626
Federal Register / Vol. 75, No. 113 / Monday, June 14, 2010 / Notices
does not require any additional
information gathering beyond what is
already required to assure conformance
with all specifications and limitations in
any given food or color additive
regulation. Label information does not
have any specific recordkeeping
requirements unique to preparing the
label. Therefore, because labeling
requirements under § 70.25 for a
particular color additive involve
information required as part of the CAP
safety review process, the estimate for
number of respondents is the same for
§ 70.25 and § 71.1, and the burden hours
for labeling are included in the estimate
for § 71.1. Also, because labeling
requirements under parts 172, 173, 179,
and 180 for particular food additives
involve information required as part of
the FAP safety review process under
§ 171.1, the burden hours for labeling
are included in the estimate for § 171.1.
Bethesda, MD 20892–7924, 301–435–0310,
whiterl@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Comparative Effectiveness Research in
Clinical Hypertension Management.
Date: June 24, 2010.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Chang Sook Kim, PhD,
Scientific Review Officer, Review Branch,
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7190,
Bethesda, MD 20892, 301–435–0287,
carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 7, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–14155 Filed 6–11–10; 8:45 am]
Dated: June 8, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4160–01–S
[FR Doc. 2010–14188 Filed 6–11–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
emcdonald on DSK2BSOYB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. app.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel.
Ruth L. Kirschstein NRSA Institutional
Research Training Grants.
Date: June 24, 2010.
Time: 1 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Roy L White, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7176,
VerDate Mar<15>2010
16:40 Jun 11, 2010
Jkt 220001
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Rehabilitation Sciences.
Date: July 9, 2010.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Jo Pelham, BA, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4102, MSC 7814, Bethesda, MD
20892, (301) 435–1786, pelhamj@csr.nih.gov.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Hematology.
Date: July 9, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Delia Tang, MD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4126, MSC 7802, Bethesda, MD
20892, 301–435–2506, tangd@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Psychopathology,
Developmental Disabilities, Stress and Aging.
Date: July 9, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: InterContinental Mark Hopkins, 1
Nob Hill, San Francisco, CA 94108.
Contact Person: Kathlyn Robbins, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182,
MSC 7848, Bethesda, MD 20892, (301) 435–
0913, robbinsk@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: BGES and NAME.
Date: July 9, 2010.
Time: 8 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting)
Contact Person: Bob Weller, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3160,
MSC 7770, Bethesda, MD 20892, (301) 435–
0694, wellerr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; ARRA:
Rehabilitation Sciences.
Date: July 9, 2010.
Time: 4 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Jo Pelham, BA, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4102, MSC 7814, Bethesda, MD
20892, (301) 435–1786, pelhamj@csr.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group; AIDS
Molecular and Cellular Biology Study
Section.
Date: July 12, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Kenneth A Roebuck, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\14JNN1.SGM
14JNN1
Agencies
[Federal Register Volume 75, Number 113 (Monday, June 14, 2010)]
[Notices]
[Pages 33624-33626]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-14155]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0258]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Submission of Petitions: Food Additive, Color Additive
(Including Labeling), and Generally Recognized as Safe Affirmation;
Submission of Information to a Master File in Support of Petitions;
Electronic Submission Using Food and Drug Administration Form 3503
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the information collection
provisions of FDA's regulations for submission of petitions, including
food and color additive petitions (including labeling) and generally
recognized as safe (GRAS) affirmations, submission of information to a
Master File in support of petitions, and electronic submission using
FDA Form 3503. This notice also notifies the public of and solicits
comments on FDA's proposed changes to Form FDA 3503 and elimination of
Form FDA 3504.
DATES: Submit either electronic or written comments on the collection
of information by August 13, 2010.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Submission of Petitions: Food Additive, Color Additive (Including
Labeling), and GRAS Affirmation; Submission of Information to a Master
File in Support of Petitions; Electronic Submission Using FDA Form
3503--21 CFR 70.25, 71.1, 170.35, 171.1, 172, 173, 179, and 180 (OMB
Control Number 0910-0016)--Revision
Section 409(a) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 348(a)) provides that a food additive shall be deemed
to be unsafe, unless: (1) The additive and its use, or intended use,
are in conformity with a regulation issued under section 409 of the act
that describes the condition(s) under which the additive may be safely
used; (2) the additive and its use, or intended use, conform to the
terms of an exemption for investigational use; or (3) a food contact
notification submitted under section 409(h) of the act is effective.
Food additive petitions (FAPs) are submitted by individuals or
companies to obtain approval of a new food additive or to amend the
conditions of use permitted under an existing food additive regulation.
Section 171.1 of FDA's regulations (21 CFR 171.1) specifies the
information that a petitioner must submit in order to establish that
the proposed use of a food additive is safe and to secure the
publication of a food additive regulation describing the conditions
under which the additive may be safely used. Parts 172, 173, 179, and
180 (21 CFR parts 172, 173, 179, and 180) contain labeling requirements
for certain food additives to ensure their safe use.
Section 721(a) of the act (21 U.S.C. 379e(a)) provides that a color
additive shall be deemed to be unsafe unless the additive and its use
are in conformity with a regulation that describes the condition(s)
under which the additive may safely be used, or the additive and its
use conform to the terms of an exemption for investigational use issued
under section 721(f) of the act. Color additive petitions (CAPs) are
submitted by individuals or companies to obtain approval of a new color
additive or a change in the conditions of use permitted for a color
additive that is already approved. Section 71.1 of the agency's
regulations (21 CFR 71.1) specifies the information that a petitioner
must submit to establish the safety of a color additive and to secure
the issuance of a regulation permitting its use. FDA's color additive
labeling requirements in Sec. 70.25 (21 CFR 70.25) require that color
additives that are to be used in food, drugs, devices, or cosmetics be
labeled with sufficient information to ensure their safe use.
FDA scientific personnel review FAPs to ensure the safety of the
intended use of the additive in or on food or that may be present in
food as a result of its use in articles that contact food. Likewise,
FDA personnel review color additive petitions to ensure the safety of
the color additive prior to its use in food, drugs, cosmetics, or
medical devices.
Under section 201(s) of the act (21 U.S.C. 321(s)), a substance is
GRAS if it is generally recognized among experts qualified by
scientific training and experience to evaluate its safety, to be safe
through either scientific procedures
[[Page 33625]]
or common use in food. The act historically has been interpreted to
permit food manufacturers to make their own initial determination that
use of a substance in food is GRAS and thereafter seek affirmation of
GRAS status from FDA. FDA reviews petitions for affirmation of GRAS
status that are submitted on a voluntary basis by the food industry and
other interested parties under authority of sections 201, 402, 409, and
701 of the act (21 U.S.C. 342, 348, and 371). To implement the GRAS
provisions of the act, FDA has set forth procedures for the GRAS
affirmation petition process in Sec. 170.35(c)(1) of its regulations
(21 CFR 170.35(c)(1)). While the GRAS affirmation petition process
still exists, FDA has not received a GRAS affirmation petition since
the establishment of the voluntary GRAS notification program and is not
expecting any during the period covered by this proposed extension of
collection of information.
Currently, interested persons may transmit regulatory submissions
to the Office of Food Additive Safety in the Center for Food Safety and
Applied Nutrition using Form FDA 3503 for FAP and Form FDA 3504 for
CAP. FDA is revising Form FDA 3503 to better enable its use for
electronic submission and to permit its use for multiple types of
submissions, which eliminates the need for Form FDA 3504. Because Form
FDA 3503 helps the respondent organize their submission to focus on the
information needed for FDA's safety review, FDA now recommends that
this form be used for FAPs and CAPs, whether submitted in electronic
format or paper format. FDA estimates that the amount of time for
respondents to complete the revised FDA Form 3503 will continue to be 1
hour. The revised Form FDA 3503 can be used to submit information to
FDA in electronic format using the Electronic Submission Gateway
portal. The revised Form FDA 3503 can be used to substitute for the
``Dear Sir'' section of 21 CFR 71.1(c) for a CAP and 21 CFR 171.1(c)
for an FAP. The revised Form FDA 3503 provides for submitters to
indicate the date of their most recent presubmission consultation
activity with FDA. The revised Form FDA 3503 can also be used to
organize information within a Master File submitted in support of
petitions according to the items listed on the form. Master Files can
be used as repositories for information that can be referenced in
multiple submissions to the agency, thus minimizing paperwork burden
for food and color additive approvals. The revised Form FDA 3503 is
formatted to accept submissions for both FAP and CAP, thus making Form
FDA 3504 redundant for collecting CAP submissions. Therefore, FDA is
eliminating Form FDA 3504.
Description of respondents: Respondents are businesses engaged in
the manufacture or sale of food, food ingredients, color additives, or
substances used in materials that come into contact with food.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per Total Operating &
21 CFR Section/ FDA Form Respondents per Response Responses Response Maintenance Costs Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
CAPs
--------------------------------------------------------------------------------------------------------------------------------------------------------
70.25,71 2 1 2 1,337 $5,600 2,674
--------------------------------------------------------------------------------------------------------------------------------------------------------
GRAS Affirmation Petitions
--------------------------------------------------------------------------------------------------------------------------------------------------------
170.35 1 or fewer 1 1 or fewer 2,614 0 2,614
--------------------------------------------------------------------------------------------------------------------------------------------------------
FAPs
--------------------------------------------------------------------------------------------------------------------------------------------------------
171.1 3 1 3 7,093 0 21,279
--------------------------------------------------------------------------------------------------------------------------------------------------------
FDA Form 3503 6 1 6 1 0 6
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total $5,600 26,573
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs associated with this collection of information.
The estimate of burden for food additive, color additive, or GRAS
affirmation petitions is based on FDA's experience and the average
number of new petitions received in calendar years 2006, 2007, 2008,
and 2009, and the total hours expended in preparing the petitions. In
compiling these estimates, FDA consulted its records of the number of
petitions received in the past four years. The figures for hours per
response are based on estimates from experienced persons in the agency
and in industry. Although the estimated hour burden varies with the
type of petition submitted, an average petition involves analytical
work and appropriate toxicological studies, as well as the work of
drafting the petition itself. The burden varies depending on the
complexity of the petition, including the amount and types of data
needed for scientific analysis.
Color additives are subjected to payment of fees for the
petitioning process. The listing fee for a color additive petition
ranges from $1,600 to $3,000, depending on the intended use of the
color and the scope of the requested amendment. A complete schedule of
fees is set forth in 21 CFR 70.19. An average of one Category A and one
Category B color additive petition is expected per year. The maximum
color additive petition fee for a Category A petition is $2,600 and the
maximum color additive petition fee for a Category B petition is
$3,000. Because an average of 2 color additive petitions are expected
per calendar year, the estimated total annual cost burden to
petitioners for this startup cost would be less than or equal to $5,600
(1 x $2,600 + 1 x $3,000 listing fees = $5,600). There are no capital
costs associated with color additive petitions.
The labeling requirements for food and color additives were
designed to specify the minimum information needed for labeling in
order that food and color manufacturers may comply with all applicable
provisions of the act and other specific labeling acts administered by
FDA. Label information
[[Page 33626]]
does not require any additional information gathering beyond what is
already required to assure conformance with all specifications and
limitations in any given food or color additive regulation. Label
information does not have any specific recordkeeping requirements
unique to preparing the label. Therefore, because labeling requirements
under Sec. 70.25 for a particular color additive involve information
required as part of the CAP safety review process, the estimate for
number of respondents is the same for Sec. 70.25 and Sec. 71.1, and
the burden hours for labeling are included in the estimate for Sec.
71.1. Also, because labeling requirements under parts 172, 173, 179,
and 180 for particular food additives involve information required as
part of the FAP safety review process under Sec. 171.1, the burden
hours for labeling are included in the estimate for Sec. 171.1.
Dated: June 7, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-14155 Filed 6-11-10; 8:45 am]
BILLING CODE 4160-01-S